HC Wainwright & Co. Maintains Buy on Immix Biopharma, Raises Price Target to $27
HC Wainwright & Co. analyst Robert Burns maintains Immix Biopharma (NASDAQ:IMMX) with a Buy and raises the price target from $25 to $27.
Last updated: 2026-11-16 15:49:40. Prices reflect the latest regular market data. Stock price data is sourced from Massive.
Immix Biopharma, Inc. (IMMX) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $7.87, with a market capitalization of $657.09M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $3.78 to $15.10. This page covers its latest market performance, valuation, price trends and company information.
$657.09M | |
$7.77 | |
$8.32 | |
$7.50 | |
$7.84 | |
182.72K | |
1.49M | |
-- | |
$15.10 | |
$3.78 | |
-- | |
-- |
Immix Biopharma, Inc. (IMMX) is currently trading at $7.87 as of 2026-11-16 15:47:00, up 0.64% ($0.05) from the previous close of $7.84
During today's regular trading session, IMMX has traded between $7.50 and $8.33, with a trading volume of 182.72K shares. The current price is near the middle of today's range.
Over the past seven days, Immix Biopharma, Inc. (IMMX) moved from $7.20 to $7.87, representing a gain of 9.24% ($0.67).
The stock traded between $7.12 and $8.89 during the period. The latest price is near the middle of the 7-day range, indicating strong upward.
The average daily volume was 1.14 million shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 36.1%
IMMX is currently trading at $7.87, placing it 36.1% of the way from its 52-week low of $3.78 to its 52-week high of $15.10. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Immix Biopharma Inc is engaged in the discovery and development of novel cell therapies for hematologic malignancies (blood cancers) and other indications. It is a clinical-stage biopharmaceutical company developing a novel class of Tissue-Specific Therapeutics TM in oncology and inflammation. Its TME Normalization Technology allows drug candidates to circulate in the bloodstream, exit through tumor blood vessels and simultaneously attack all components of the TME. Its product candidates include CAR-T NXC-201 for autoimmune diseases, and IMX-110 for treatment of soft tissue sarcoma.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 21 |
| Exchange | NASDAQ |
| Company Website |
Latest news related to Immix Biopharma, Inc. and IMMX stock.
HC Wainwright & Co. analyst Robert Burns maintains Immix Biopharma (NASDAQ:IMMX) with a Buy and raises the price target from $25 to $27.
Immix Biopharma (NASDAQ:IMMX) reported quarterly losses of $(0.19) per share which met the analyst consensus estimate. This is a 20.83 percent increase over losses of $(0.24) per share from the same period last year.
Eligible investors can buy real shares of Immix Biopharma, Inc. (IMMX) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.
Stock prices and market data on this page, including price changes and market status, are provided by Massive and other third-party news and data platforms. Market data may be delayed and may differ from prices on other platforms or the prices at which trades are executed on MEXC. MEXC does not guarantee the accuracy, completeness, or timeliness of third-party data. MEXC offers trading products related to IMMX, including Stocks, Tokenized Stocks, and Stock Futures.
The stock price information displayed on this page is provided for reference purposes only and may be delayed or differ from real-time market data. Prices, charts, and related metrics do not constitute investment advice and should not be relied upon for trading or investment decisions. MEXC is not responsible for any losses incurred based on the stock price information provided on this page. Please refer to official market sources or consult licensed financial professionals before making any investment decisions.
Estimate the value between IMMX shares and USD.
IMMX Shares to USD
1.00 IMMX shares = 7.865 USD
Calculations are estimates based on the latest available price and are for reference only.